The uniqueness of the Spodoptera frugiperda engineering lies in the insect cell line's ability to correctly fold complex eukaryotic proteins and add glycan modifications. This characteristic, coupled with their rapid growth and ease of genetic manipulation, makes these cell lines highly adaptable platforms for protein production and glycobiology research. In particular, the use of these cell lines for chemoenzymatic glycoengineering provides a unique tool for producing customized glycoproteins with precise and predictable glycan structures that are unachievable with other systems.

Spodoptera frugiperda Engineering Service at CD BioGlyco

CD BioGlyco has developed the cutting-edge GlycoChas™ Cells platform, which features a wide range of chassis species, including multiple Insect Chassis. These chassis are carefully designed and optimized to support a variety of complex biological experiments and engineering applications. It is particularly worth mentioning that S. frugiperda engineering service we provide, based on our GlycoChas™ provides clients with efficient and accurate S. frugiperda metabolic engineering, cell engineering, glycosyltransferase engineering, synthetic O-glycan engineering, and protein engineering services.

• Metabolic Pathway Engineering

• Metabolic pathway reconstruction: Through metabolic pathway engineering, we optimize the glycan metabolism pathway of S. frugiperda and improve the synthesis efficiency of specific glycan substances. For example, the ability of S. frugiperda to synthesize certain rare glycans can be enhanced by introducing exogenous genes or modifying endogenous genes.

• Metabolic flow analysis and optimization: We real-time monitor metabolic flow changes of S. frugiperda under different physiological states using isotope labeling and mass spectrometry analysis. We analyze this data to optimize metabolic flow and improve the production and quality of carbohydrates.

• Cell Engineering

  The importance of S. frugiperda in synthetic glycobiology depends on its engineered cell lines, particularly the Sf9 and Sf21 cell lines. These cell lines are widely used in bioengineering to produce recombinant proteins using baculovirus expression vector systems. This technology utilizes insect cells to produce eukaryotic proteins with post-translational modifications such as glycosylation, which is difficult to achieve in bacterial or yeast systems. This makes the Sf9/Sf21 cell line invaluable for the production of complex proteins for structural and functional studies, vaccine production, and therapeutics.

• Cell line establishment and optimization: We establish a stable S. frugiperda cell line to study its glycan metabolism characteristics and regulatory mechanism in vitro. These cell lines serve as bioreactors for the production of specific glycans. Improve the yield and purity of carbohydrates by optimizing cell culture conditions and metabolic pathways.

• Large-scale culture and fermentation: S. frugiperda has a rapid growth rate and strong metabolic capacity, making it suitable for large-scale culture and fermentation. Efficient production and cost control of glycans are achieved by optimizing the fermentation process and reactor design.

• Glycosyltransferase Engineering

  S. frugiperda glycosyltransferase engineering techniques include expressing mammalian glycosyltransferases or creating S. frugiperda strains with enhanced glycosyltransferase activity to synthesize target glycan structures.

• Identification and cloning of glycosyltransferase: First, it is necessary to identify and clone the enzyme gene with specific glycosyl transfer activity. These genes come from S. frugiperda or from other species.

• Gene expression and regulation: We express the cloned glycosyltransferase gene in S. frugiperda, and control its expression level through gene editing technology. This can alter the extent and type of glycosylation modifications in insects.

• Analysis of glycosylation products: We analyze the glycosylation products in insects after engineering glycosyltransferases, and evaluate their impact on the synthesis and properties of carbohydrates.

• Synthetic O-glycan Engineering

  This technology aims to transform S. frugiperda cells and perform human-like O-glycosylation on recombinant proteins. While insects naturally only carry out simple forms of O-glycosylation, through genetic engineering, the more complex form (mucin-type O-glycosylation) commonly seen in humans can be recreated, resulting in a more realistically human appearance in these insects glycoprotein cells.

• Glycoprotein Engineering

  Glycoprotein engineering aims to optimize the structure and function of glycoproteins in S. frugiperda by regulating their synthesis and modification.

• Glycoprotein structure and function analysis: By understanding the structure and functional characteristics of the target glycoprotein, we determine the key factors affecting its stability and activity.

• Gene editing and regulation: Gene editing technology is used to knock out or down-regulate genes related to glycoprotein synthesis and modification to reduce non-specific glycosylation or increase the proportion of specific glycosylation. At the same time, the synthesis efficiency of glycoprotein is improved by up-regulating key enzyme genes.

• Purification and identification of glycoproteins: After glycoprotein engineering, the glycoproteins synthesized in insects are purified and identified through chromatographic separation, mass spectrometry analysis and other methods.

Applications of S. frugiperda Engineering

• Specific glycosyltransferases are expressed in S. frugiperda cells to achieve in vitro synthesis of complex glycan chains through gene editing technology. These enzymes catalyze glycosylation reactions to produce glycan chains with specific structures and functions.
• S. frugiperda engineering can be used for the construction of disease models and drug screening. The mechanisms of disease occurrence and development can be studied by simulating abnormal glycosylation in human diseases. At the same time, drug screening using the S. frugiperda cell line quickly identifies drug candidates with potential therapeutic effects.
• S. frugiperda can be engineered to produce glycoproteins. The ability to manipulate glycosylation could potentially improve the therapeutic properties of these proteins by enhancing their stability, solubility, and immunogenicity.

CD BioGlyco provides efficient S. frugiperda engineering services. We specialize in providing S. frugiperda chassis and its high-quality glycan/glycoprotein products. Our services cover the entire process from basic research to product development. Clients are welcome to contact us and we look forward to working with you to meet your specific needs.

• Drosophila melanogaster Engineering Service
• Trichoplusia ni Engineering Service